Sign in
CompletedPhase 1

Safety and Tolerability of F012 in Patients With Hyperuricemia and Gout

Key facts

Who runs it
The Affiliated Hospital of Qingdao University
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 1
People taking part
40 people enrolled
Started
11 Jun 2024
Ended
30 Nov 2025
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • PEGylated uricase
  • F012 placebo
Record updated
16 November 2026

Who can take part

Age
18 years to 60 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 31 criteriaShow less

Who can take part

  • Hyperuricemia patients: Stop uric acid lowering treatment for more than 7 days, and take two non same day treatments within 7 days.Fasting blood uric acid level ≥ 480 μ mol/L
  • Patients with or without occasional gout: Complies with the 2015 American College of Rheumatology ACR/European Union Against Rheumatism (EULAR) jointly launch diagnosis of gout standardized and screened with less than 2 gout attacks in the previous year
  • The weight of male subjects is ≥ 50.0kg, and the weight of female subjects is ≥ 45.0kg. Weight refers toBMI is between 18~30kg/m2, including the critical value
  • The subjects have a good daily routine and are able to maintain good communication and compliance with the researchersAdhere to various requirements of clinical trials
  • Voluntarily sign the informed consent form

Who cannot take part

  • Those with a history of tuberculosis within 6 months before screening
  • Organ transplant patients
  • History of acute gout attacks within 2 weeks prior to the screening period or being in the acute gout attack phase at the time of screening
  • Individuals who have previously received uricase therapy
  • Individuals with herpes zoster infection, uncorrected dehydration, acidosis, or currently using nephrotoxic drugs
  • Those who have undergone surgical procedures within 3 months prior to the first administration, or plan to undergo surgical procedures during the study period
  • Individuals who have received any other clinical trial drug/device treatment within 3 months prior to the first administration
  • Those who consume more than 1L of strong tea, coffee, and/or caffeinated beverages per day within the first 3 months prior to the first administration; Eating high purine foods (such as animal organs, seafood, etc.) within 48 hours before administration
  • Individuals who donate blood or experience significant blood loss (≥ 400mL, excluding normal menstrual blood loss in females), receive blood transfusions, or use blood products within 3 months prior to the first administration of medication
  • Smoking ≥ 5 cigarettes per day within 3 months before the first administration, or unwilling to ban any tobacco products during the trial period
  • Positive alcohol breath test results, or those who have been drinking alcohol for more than 14 units per week within the past 3 months before the first administration (1 unit of alcohol equals approximately 285mL of beer, 25mL of strong liquor, or 100mL of wine)
  • Individuals with a history of drug abuse (including repeated and excessive use of various types of narcotics and psychotropic drugs for non-medical purposes) or positive drug abuse screening results within one year prior to the first administration
  • Individuals who have received inactivated vaccines within one month prior to the first dose, received live/attenuated vaccines within three months prior to the first dose, or plan to receive any vaccines during the trial period
  • Female subjects who engage in unprotected sexual activity during pregnancy, lactation, or 2 weeks prior to administration, as well as those who have a pregnancy plan or a plan to donate sperm or eggs within 6 months after the end of the trial and are unwilling to use a medically recognized contraceptive method (such as intrauterine devices or condoms) or abstain during the trial period
  • Malignant tumor patients
  • Individuals with drug allergies
  • Individuals with clear blood system disorders or abnormal coagulation function
  • Virological tests show positive results for HCV antibodies, HIV antibodies, and Treponema pallidum antibodies; HBV: HBsAg and/or HBcAb positive individuals with HBV-DNA above the upper limit of normal values
  • Individuals with severe mental and psychological disorders, cognitive impairments, and a history of mental illness
  • Individuals with a tendency to bleed, such as those who experience bleeding or subcutaneous bleeding due to mild collisions during normal times
  • People who have difficulty with venipuncture, cannot tolerate venipuncture, and have a history of needle and blood dizziness
  • Individuals with a history of glucose-6-phosphate dehydrogenase (G6PD) deficiency or abnormal G6PD with clinical significance, history of catalase deficiency, history of autoimmune diseases, and history of atopic allergic diseases
  • Patients with unstable angina pectoris, serious arrhythmia requiring drug intervention, congestive heart failure [NYHA rating ≥ Grade II], uncontrolled hypertension (more than 150/95 mmHg), poor blood glucose control in diabetes patients (i.e. glycosylated hemoglobin HbA1c ≥ 7%), acute stroke, severe or chronic hemorrhagic digestive system disease, pleural effusion, abdominal effusion, etc
  • Individuals with creatinine levels greater than 1.5 times the upper limit of normal; Individuals with serum transaminase levels exceeding 1.5 times the upper limit of normal range
  • Patients with secondary hyperuricemia
  • Those who may not be able to complete this study due to other reasons or who the researcher deems should not be included

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study is a randomized, double-blind, placebo-controlled single dose escalation (SAD) study conducted in patients with hyperuricemia with or without gout. The plan is to conduct ramp ups in 5 dose groups of 1mg, 2mg, 4mg, 6mg, and 8mg (adjustable during the study), with 8 subjects in each dose group and a total of 40 subjects. The sentinel method will be used for each dose group, with 2 subjects in the first group (1A+1P) followed by 6 subjects in the second group (5A+1P), to observe safety and tolerability.

The 2 groups in the trial

  • Placebo groupPlacebo, for comparison

    Single intravenous injection of placebo

    Treatment: F012 placebo

  • F012 experimental groupTreatment being tested

    Single intravenous injection of F012

    Treatment: PEGylated uricase

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Double-blind, Placebo-controlled, Single Dose Escalation Phase I Clinical Study Evaluating the Safety and Tolerability of F012 in Patients With Hyperuricemia and Gout
Record updated
16 November 2026